Johnson & Johnson 3QFY18 sales increased 3.6 percent

Johnson & Johnson reported sales of USD 20.3 billion for the third quarter of 2018, an increase of 3.6 percent as compared to the third quarter of 2017. Operational sales results increased 5.5 percent, partially offset by the negative impact of currency of 1.9 percent. Domestic sales increased 3.6 percent. International sales increased 3.5 percent, reflecting operational growth of 7.5 percent and a negative currency impact of 4.0 percent. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 6.1 percent, domestic sales increased 3.9 percent, and international sales increased 8.5 percent. Net earnings and diluted earnings per share for the third quarter of 2018 were USD 3.9 billion and USD 1.44, respectively.

Third-quarter 2018 net earnings included after-tax intangible amortization expense of approximately USD 1.0 billion and a net charge for after-tax special items of approximately USD 0.7 billion, primarily consisting of a non-cash charge attributed to a partial write-down of an in-process R&D asset associated with the acquisition of Alios BioPharma Inc. Third-quarter 2017 net earnings included an after-tax intangible amortization expense of approximately USD 0.9 billion and a charge for after-tax special items of approximately USD 0.5 billion.

Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were USD 5.6 billion and adjusted diluted earnings per share were USD 2.05, representing increases of 7.3 percent and 7.9 percent, respectively, as compared to the same period in 2017.